Immunocore saw 70% of first-line patients alive at two years. Can two T-cell engagers really beat KIMMTRAK alone?
Immunocore reported 70% two-year survival with KIMMTRAK plus brenetafusp, but a randomised Phase 2/3 trial must confirm the signal.
Features & Analysis
Pharma & Biotech
Immunocore reports 70% two-year survival with dual T-cell engager combination in uveal melanoma
Immunocore’s brenetafusp plus Kimmtrak posted 70% two-year survival in 17 first-line uveal melanoma patients, prompting a Phase 2/3 trial.
Pharma & Biotech
A promising eye cancer drug shrank tumors in phase 1, so why did Novartis stop developing DYP688?
DYP688 showed early activity and manageable toxicity in metastatic uveal melanoma, but Novartis has halted development despite the clinical signal.
Pharma & Biotech
Could five-year survival data position KIMMTRAK as a durable standard in uveal melanoma care
Discover how Immunocore’s five-year KIMMTRAK data could reshape survival expectations in metastatic uveal melanoma. Read the full analysis.